Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06167655 · ClinicalTrials.gov registry record · NA
A Pivotal Study Evaluating Safety AND Efficacy OF THE Shiratronics Migraine Therapy System
A NA study of Headache Migraine Chronic, sponsored by ShiraTronics.
- Recruiting
- Registry status
- NA
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT06167655: Recruiting NA study of Headache Migraine Chronic, sponsored by ShiraTronics.
NCT06167655 is a NA study of Headache Migraine Chronic that is actively recruiting participants, run by ShiraTronics. The registered enrollment target is 250 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06167655, a NA study of Headache Migraine Chronic, is actively recruiting participants, sponsored by ShiraTronics.
- RECRUITING
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine. The study hypothesis to be tested is the mean reduction in mean monthly headache days between patients in treatment versus sham.
Primary Outcome
Mean monthly headache days
Conditions Studied
Interventions
- DEVICE Neurostimulator
Study Locations (20)
Minnesota
- iSpine Clinics - Chaska
- University of Minnesota - Minneapolis
- Mayo Clinic Rochester - Rochester
New York
- Dent Neurologic Institute - Amherst
- Northwell Health Physician Partners - New York
- Montefiore Health - New York
California
- UC San Diego Health - La Jolla
- Neurovations - Napa
North Carolina
- Queen City Clinical Research - Charlotte
- The Center for Clinical Research - Winston-Salem
Pennsylvania
- Argires Marotti Neurological Associates - Lancaster
- Jefferson Headache Center - Philadelphia
Arizona
- Mayo Clinic Arizona - Scottsdale
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- Barolat Neuroscience - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-05-29 |
| Est. Completion | 2026-08-30 |
| Phase | NA |
What NCT06167655 shows while recruiting
NCT06167655 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Headache Migraine Chronic appearing as the primary indexed condition, and to 1 intervention - of which Neurostimulator is the first listed.
NCT06167655 names 20 study sites across 13 states, led by Minnesota, New York, California.
Frequently Asked Questions
What is clinical trial NCT06167655 about?
NCT06167655 is a clinical study titled "A Pivotal Study Evaluating Safety AND Efficacy OF THE Shiratronics Migraine Therapy System". Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine. The study hypothesis to be tested is the mean reduction in mean monthly headache days between patients in treatment versus sham.
What is the current status of trial NCT06167655?
This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2024-05-29. Estimated completion is 2026-08-30.
What conditions does trial NCT06167655 study?
This clinical trial studies the following conditions: Headache Migraine Chronic.
What interventions are being tested in trial NCT06167655?
The interventions under investigation include: Neurostimulator (DEVICE).
Who is sponsoring clinical trial NCT06167655?
This trial is sponsored by ShiraTronics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06167655 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06167655's enrollment target sits among peer trials
250 410th of 2000 higher than 1,567 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI